Show simple item record

dc.contributor.authorBravo, Lidia
dc.contributor.authorLLorca-Torralba, Meritxell
dc.contributor.authorBerrocoso, Esther
dc.contributor.authorMicó, Juan Antonio
dc.contributor.otherNeurocienciases_ES
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2020-01-24T10:25:51Z
dc.date.available2020-01-24T10:25:51Z
dc.date.issued2019-11
dc.identifier.issn1662-453X
dc.identifier.urihttp://hdl.handle.net/10498/22180
dc.description.abstractMonoamines are involved in regulating the endogenous pain system and indeed, peripheral and central monoaminergic dysfunction has been demonstrated in certain types of pain, particularly in neuropathic pain. Accordingly, drugs that modulate the monaminergic system and that were originally designed to treat depression are now considered to be first line treatments for certain types of neuropathic pain (e.g., serotonin and noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced by these drugs seems to be mediated by inhibiting the reuptake of these monoamines, thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particular interest to study the monoaminergic mechanisms involved in the development and maintenance of chronic pain. Other analgesic drugs may also be used in combination with monoamines to facilitate descending pain inhibition (e.g., gabapentinoids and opioids) and such combinations are often also used to alleviate certain types of chronic pain. By contrast, while NSAIDs are thought to influence the monoaminergic system, they just produce consistent analgesia in inflammatory pain. Thus, in this review we will provide preclinical and clinical evidence of the role of monoamines in the modulation of chronic pain, reviewing how this system is implicated in the analgesic mechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs and histaminergic drugses_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherFRONTIERS MEDIA SAes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceFront. Neurosci. 13:1268es_ES
dc.subjectchronic paines_ES
dc.subjectneuropathic paines_ES
dc.subjectmonoamineses_ES
dc.subjectantidepressantses_ES
dc.subjectnoradrenalinees_ES
dc.subjectserotonines_ES
dc.titleMonoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Paines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3389/fnins.2019.01268


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional